Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)

NCT03196765 is registered in ClinicalTrials.gov with NeuroVia, Inc. as lead sponsor.

NCT NCT03196765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03196765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)
Lead sponsor
NeuroVia, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
August 31, 2018
Completion date
December 1, 2020
Enrollment
0 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked adrenoleukodystrophy